Kyverna Therapeutics, Immunome, Almonty Industries, and Other Major Stocks Rise on Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 100 points on Monday.
Kyverna Therapeutics Surge: Kyverna Therapeutics Inc. shares rose 31% to $11.49 following the announcement of positive topline data from its Phase 2 trial of mivocabtagene autoleucel for stiff person syndrome.
Other Notable Stock Gains: Beneficient, Immunome Inc., and Falcon’s Beyond Global recorded significant gains, with increases of 29.3%, 25.5%, and 14% respectively.
Additional Stock Movements: Several other companies, including Almonty Industries and NovaBay Pharmaceuticals, also saw notable increases in their stock prices, contributing to a generally positive day for select stocks despite the overall market decline.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OLMA is 36.83 USD with a low forecast of 20.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.190
Low
20.00
Averages
36.83
High
55.00
Current: 29.190
Low
20.00
Averages
36.83
High
55.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
